Yılmaz Baris, Kose Ozkan, Karahan Nazım, Tumentemur Gamze, Ertan Mehmet Barıs, Ozdemir Guzelali, Sirin Evrim
Fatih Sultan Mehmet Training & Research Hospital, Department of Orthopedics and Traumatology, University of Health Sciences, Istanbul, Turkey.
Antalya Training & Research Hospital, Department of Orthopedics and Traumatology, University of Health Sciences, Antalya, Turkey.
Connect Tissue Res. 2024 May;65(3):226-236. doi: 10.1080/03008207.2024.2349817. Epub 2024 May 9.
This study aimed to evaluate whether cilostazol (phosphodiesterase III inhibitor) could enhance the healing of Achilles tendon ruptures in rats.
The Achilles tendons of 24 healthy male adult rats were incised and repaired. The rats were randomly allocated to cilostazol and control groups. The cilostazol group received daily intragastric administration of 50 mg/kg cilostazol for 28 days, while the control group did not receive any medication. The rats were sacrificed on the 30th day, and the Achilles tendon was evaluated for biomechanical properties, histopathological characteristics, and immunohistochemical analysis.
All rats completed the experiment. The Movin sum score of the control group was significantly higher ( = 0.008) than that of the cilostazol group, with means of 11 ± 0.63 and 7.50 ± 1.15, respectively. Similarly, the mean Bonar score was significantly higher ( = 0.026) in the control group compared to the cilostazol group (8.33 ± 1.50 vs. 5.5 ± 0.54, respectively). Moreover, the Type I/Type III Collagen ratio was notably higher ( = 0.016) in the cilostazol group (52.2 ± 8.4) than in the control group (34.6 ± 10.2). The load to failure was substantially higher in the cilostazol group than in the control group ( = 0.034), suggesting that the tendons in the cilostazol group were stronger and exhibited greater resistance to failure.
The results of this study suggest that cilostazol treatment significantly improves the biomechanical and histopathological parameters of the healing Achilles tendon in rats. Cilostazol might be a valuable supplementary therapy in treating Achilles tendon ruptures in humans. Additional clinical studies are, however, required to verify these outcomes.
本研究旨在评估西洛他唑（磷酸二酯酶III抑制剂）是否能促进大鼠跟腱断裂的愈合。
切开并修复24只健康成年雄性大鼠的跟腱。将大鼠随机分为西洛他唑组和对照组。西洛他唑组每天经胃给予50mg/kg西洛他唑，持续28天，而对照组不接受任何药物治疗。在第30天处死大鼠，对跟腱进行生物力学性能、组织病理学特征和免疫组织化学分析。
所有大鼠均完成实验。对照组的Movin总分显著高于西洛他唑组（=0.008），分别为11±0.63和7.50±1.15。同样，对照组的平均博纳尔评分显著高于西洛他唑组（=0.026）（分别为8.33±1.50和5.5±0.54）。此外，西洛他唑组的I型/III型胶原蛋白比率显著高于对照组（=0.016）（52.2±8.4 vs. 34.6±10.2）。西洛他唑组的破坏载荷显著高于对照组（=0.034），表明西洛他唑组的肌腱更强，对破坏的抵抗力更大。
本研究结果表明，西洛他唑治疗可显著改善大鼠愈合跟腱的生物力学和组织病理学参数。西洛他唑可能是治疗人类跟腱断裂的一种有价值的辅助疗法。然而，需要更多的临床研究来验证这些结果。
